drugset / Trial / NCT04516811

Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19

NCT04516811

Phase 3 Terminated 102 enrolled South African National Blood Service
RandomizedParallel-groupTriple-blindTreatment

Summary

A prospective, randomized, placebo-controlled, double-blinded, phase III clinical trial of the therapeutic use of convalescent plasma in the treatment of patients with moderate to severe COVID-19

Timeline

Start
2020-09-21
Primary completion
2021-12-30
Completion
2022-07-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Convalescent Plasma Protein / enzyme biologic

Indications